Pancreatic Cancer Trial, Recruiting NCT03536793 Sponsor: Hull University Teaching Hospitals NHS Trust Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT03536793
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older who are able to give written consent to participate
  • People diagnosed with localised pancreatic cancer where surgery (such as removal of part or all of the pancreas) is possible
  • People diagnosed with localised pancreatic cancer that cannot be operated on, who have been referred for further management
  • People who have cysts on the pancreas where their medical team has agreed that further investigation procedures (such as fluid sampling using a needle guided by ultrasound) are needed
  • People with pancreatic cysts where the medical team has agreed the lesions can be removed by surgery and are suspicious for cancer
  • People referred for a procedure to drain fluid collections around the pancreas caused by a severe episode of pancreatitis
  • People referred for gallbladder removal due to gallbladder inflammation or gallstones
  • People scheduled to have an endoscopy (a camera examination of the digestive tract) to investigate indigestion symptoms

Who may not be able to join:

  • People who are unable to provide written consent to participate
  • People who have another known cancer, whether currently active or considered fully cleared within the last 5 years
  • People with HIV, hepatitis C, or any other known infectious communicable disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anthony Maraveyas, Hull University Teaching Hospitals NHS Trust

Phone: 01482 461245

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hull University Teaching Hospitals NHS Trust
Registry
ClinicalTrials.gov
Start date
24 October 2018
Est. completion
28 February 2027

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Measurement of the accuracy of protein markers (e.g., TF, AM) in detecting early stage pancreatic cancer by comparison of laboratory results from ELISA assays and platform technologies to patient clinical data.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov